Table 4.

Claim-based prevalence of kidney stones medication use by medication class among children with kidney stones and with continuous enrollment in private insurance for 120 days following the kidney stone event, overall and by year, 2005-2016^*

	All years	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Total kidney stone events Prevale nce by medication class	16,815	1,432	1,581	1,577	1,569	1,576	1,486	1,462	1,377	1,308	1,130	1,200	1,117
Any medication class	46.9	41.1	43.6	46.7	45.6	47.1	48.1	49.2	49.8	51.5	49.1	49.3	42.7
Any medication class except opioids	17.9	7.7	8.0	11.4	13.2	13.1	16.3	21.3	23.3	27.5	28.0	28.5	26.1
Alkalizing agent	7.4	5.7	5.6	7.4	7.2	6.5	7.8	7.7	8.9	9.7	8.0	8.1	6.5
Ammonia detoxicant	0.01	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Heavy metal antago nist	0.02	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0
Opiate agonist	39.9	36.7	39.3	41.4	40.5	41.8	41.1	41.3	41.5	42.1	40.7	38.8	32.0
Alpha blockers	10.6	1.5	1.8	4.2	5.9	6.7	8.8	13.8	14.6	17.9	20.4	20.8	20.1
Calcium channel blockers	0.5	0.6	0.5	0.1	0.4	0.3	0.4	0.6	0.7	0.7	0.8	1.2	0.6
Other	0.3	0.2	0.1	0.6	0.4	0.4	0.5	0.1	0.3	0.3	0.1	0.0	0.0